A novel cognitive-functional composite measure to detect changes in early Alzheimer's disease: Test–retest reliability and feasibility

Roos J. Jutten; John Harrison; Philippe R. Lee Meeuw Kjoe; Esther M. Opmeer; Niki S. M. Schoonenboom; Frank Jan de Jong; Craig W. Ritchie; Philip Scheltens; Sietske A. M. Sikkes

doi:10.1016/j.dadm.2017.12.002

A novel cognitive-functional composite measure to detect changes in early Alzheimer's disease: Test–retest reliability and feasibility

Roos J. Jutten, John Harrison, Philippe R. Lee Meeuw Kjoe, Esther M. Opmeer, Niki S. M. Schoonenboom, Frank Jan de Jong, Craig W. Ritchie, Philip Scheltens, Sietske A. M. Sikkes

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Introduction: To improve the detection of changes in Alzheimer's disease (AD), we designed the cognitive-functional composite (CFC). As a first validation step, we investigated its test–retest reliability and feasibility of use. Methods: We performed a test–retest study with 2–3 weeks between assessments, including patients with mild cognitive impairment (MCI) or mild AD dementia and cognitively healthy participants. We calculated intraclass correlation coefficients (ICCs) type absolute agreement for all CFC measures and compared baseline and retest scores using paired-samples t-tests. We evaluated feasibility by interviewing participants. Results: Forty-three patients (40% female, mean age = 69.9) and 30 controls (50% female, mean age = 65) were included. Subtest intraclass correlation coefficients ranged from.70 to.96. We found negligible improvements after retesting on only two subtests. Overall, patients perceived the administration of the CFC as feasible. Discussion: The CFC is a stable and feasible measure in MCI and mild AD dementia, and thereby meets important quality metrics for clinically meaningful outcome measures.

Original language	English
Pages (from-to)	153-160
Journal	Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
Volume	10
DOIs	https://doi.org/10.1016/j.dadm.2017.12.002
Publication status	Published - 2018

Access to Document

10.1016/j.dadm.2017.12.002

Cite this

Jutten, R. J., Harrison, J., Lee Meeuw Kjoe, P. R., Opmeer, E. M., Schoonenboom, N. S. M., de Jong, F. J., ... Sikkes, S. A. M. (2018). A novel cognitive-functional composite measure to detect changes in early Alzheimer's disease: Test–retest reliability and feasibility. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 10, 153-160. https://doi.org/10.1016/j.dadm.2017.12.002

Jutten, Roos J. ; Harrison, John ; Lee Meeuw Kjoe, Philippe R. ; Opmeer, Esther M. ; Schoonenboom, Niki S. M. ; de Jong, Frank Jan ; Ritchie, Craig W. ; Scheltens, Philip ; Sikkes, Sietske A. M. / A novel cognitive-functional composite measure to detect changes in early Alzheimer's disease: Test–retest reliability and feasibility. In: Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring. 2018 ; Vol. 10. pp. 153-160.

@article{7749785a9d454424b599fe89665f6631,

title = "A novel cognitive-functional composite measure to detect changes in early Alzheimer's disease: Test–retest reliability and feasibility",

abstract = "Introduction: To improve the detection of changes in Alzheimer's disease (AD), we designed the cognitive-functional composite (CFC). As a first validation step, we investigated its test–retest reliability and feasibility of use. Methods: We performed a test–retest study with 2–3 weeks between assessments, including patients with mild cognitive impairment (MCI) or mild AD dementia and cognitively healthy participants. We calculated intraclass correlation coefficients (ICCs) type absolute agreement for all CFC measures and compared baseline and retest scores using paired-samples t-tests. We evaluated feasibility by interviewing participants. Results: Forty-three patients (40{\%} female, mean age = 69.9) and 30 controls (50{\%} female, mean age = 65) were included. Subtest intraclass correlation coefficients ranged from.70 to.96. We found negligible improvements after retesting on only two subtests. Overall, patients perceived the administration of the CFC as feasible. Discussion: The CFC is a stable and feasible measure in MCI and mild AD dementia, and thereby meets important quality metrics for clinically meaningful outcome measures.",

author = "Jutten, {Roos J.} and John Harrison and {Lee Meeuw Kjoe}, {Philippe R.} and Opmeer, {Esther M.} and Schoonenboom, {Niki S. M.} and {de Jong}, {Frank Jan} and Ritchie, {Craig W.} and Philip Scheltens and Sikkes, {Sietske A. M.}",

year = "2018",

doi = "10.1016/j.dadm.2017.12.002",

language = "English",

volume = "10",

pages = "153--160",

journal = "Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring",

issn = "2352-8729",

publisher = "Elsevier BV",

}

Jutten, RJ, Harrison, J, Lee Meeuw Kjoe, PR, Opmeer, EM, Schoonenboom, NSM, de Jong, FJ, Ritchie, CW, Scheltens, P & Sikkes, SAM 2018, 'A novel cognitive-functional composite measure to detect changes in early Alzheimer's disease: Test–retest reliability and feasibility', Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, vol. 10, pp. 153-160. https://doi.org/10.1016/j.dadm.2017.12.002

A novel cognitive-functional composite measure to detect changes in early Alzheimer's disease: Test–retest reliability and feasibility. / Jutten, Roos J.; Harrison, John; Lee Meeuw Kjoe, Philippe R.; Opmeer, Esther M.; Schoonenboom, Niki S. M.; de Jong, Frank Jan; Ritchie, Craig W.; Scheltens, Philip ; Sikkes, Sietske A. M.

In: Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, Vol. 10, 2018, p. 153-160.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - A novel cognitive-functional composite measure to detect changes in early Alzheimer's disease: Test–retest reliability and feasibility

AU - Jutten, Roos J.

AU - Harrison, John

AU - Lee Meeuw Kjoe, Philippe R.

AU - Opmeer, Esther M.

AU - Schoonenboom, Niki S. M.

AU - de Jong, Frank Jan

AU - Ritchie, Craig W.

AU - Scheltens, Philip

AU - Sikkes, Sietske A. M.

PY - 2018

Y1 - 2018

N2 - Introduction: To improve the detection of changes in Alzheimer's disease (AD), we designed the cognitive-functional composite (CFC). As a first validation step, we investigated its test–retest reliability and feasibility of use. Methods: We performed a test–retest study with 2–3 weeks between assessments, including patients with mild cognitive impairment (MCI) or mild AD dementia and cognitively healthy participants. We calculated intraclass correlation coefficients (ICCs) type absolute agreement for all CFC measures and compared baseline and retest scores using paired-samples t-tests. We evaluated feasibility by interviewing participants. Results: Forty-three patients (40% female, mean age = 69.9) and 30 controls (50% female, mean age = 65) were included. Subtest intraclass correlation coefficients ranged from.70 to.96. We found negligible improvements after retesting on only two subtests. Overall, patients perceived the administration of the CFC as feasible. Discussion: The CFC is a stable and feasible measure in MCI and mild AD dementia, and thereby meets important quality metrics for clinically meaningful outcome measures.

AB - Introduction: To improve the detection of changes in Alzheimer's disease (AD), we designed the cognitive-functional composite (CFC). As a first validation step, we investigated its test–retest reliability and feasibility of use. Methods: We performed a test–retest study with 2–3 weeks between assessments, including patients with mild cognitive impairment (MCI) or mild AD dementia and cognitively healthy participants. We calculated intraclass correlation coefficients (ICCs) type absolute agreement for all CFC measures and compared baseline and retest scores using paired-samples t-tests. We evaluated feasibility by interviewing participants. Results: Forty-three patients (40% female, mean age = 69.9) and 30 controls (50% female, mean age = 65) were included. Subtest intraclass correlation coefficients ranged from.70 to.96. We found negligible improvements after retesting on only two subtests. Overall, patients perceived the administration of the CFC as feasible. Discussion: The CFC is a stable and feasible measure in MCI and mild AD dementia, and thereby meets important quality metrics for clinically meaningful outcome measures.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85041481072&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/29780863

U2 - 10.1016/j.dadm.2017.12.002

DO - 10.1016/j.dadm.2017.12.002

M3 - Article

C2 - 29780863

VL - 10

SP - 153

EP - 160

JO - Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring

JF - Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring

SN - 2352-8729

ER -